CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0733 (clinicaltrials.gov NCT No: NCT00492050)
Title:Primary Treatment of Waldenstrom's Macroglobulinemia with Bortezomib (Velcade®) and Rituximab followed by autologous stem cell collection
Principal Investigator:Sheeba K. Thomas
Treatment Agent:Bortezomib; Rituximab
Study Status:Closed
Study Description:The main goal of this clinical research study is to learn if Velcade ®
(bortezomib) given with rituximab can help to control WM. This drug
combination will allow researchers to collect your stem cells in case it is
possible to transplant the stem cells as treatment if your WM gets worse.
Researchers will also look at the safety and tolerability of this drug
combination followed by treatment with other drug combinations.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase II
Treatment Agents:Bortezomib
Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:not applicable
Supported By:N/A
Return Visit:Within 1 week prior to the start of each cycle of chemotherapy, and every 3
months thereafter until partial response or better is achieved then follow up
every 6 months
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sheeba K. Thomas
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults